Introduction. Ovarian cancer represents the deadliest gynecological malignancy. The aim of this study is to validate the predictive value of Cancer antigen-125 Elimination rate constant K score regarding progression-free survival among patients with Stage IIIc-IV high-grade serous ovarian cancer according to the International Federation of Gynecology and Obstetrics, treated with bevacizumab. Additionally, the study aims to determine the significance of a score in the assessment of progression-free survival in relation to operation status and disease stage. Material and Methods. The retrospective study was conducted at the Oncology Institute of Vojvodina and included 56 patients treated for high-grade serous ovarian cancer. The treatment protocol consisted of chemotherapy with paclitaxel and carboplatin, followed by bevacizumab maintenance therapy. The Cancer Antigen- 125 Elimination Rate Constant K score was calculated using three Cancer Antigen 125 tumor marker values. Based on this calculation, the score was dichotomized into favorabe (?1) and unfavorable (<1) groups. Results. The analysis of the score?s impact on progression-free survival revealed that patients with a score ?1 had longer mean survival time compared to a score <1 (19.4 vs 17.0 months). This difference was not statistically significant (p=0.549). The operation status in relation to a score was the only statistically significant factor with progression-free survival benefit (p=0.002). Conclusion. In our study, Cancer antigen- 125 Elimination rate constant K score did not emerge as a statistically significant prognostic factor for identifying patients most likely to benefit from bevacizumab. The operative status showed significant predictive value.
Introduction. Low-grade serous ovarian carcinoma is a distinct and relatively uncommon histologic subtype of epithelial ovarian cancer, characterized by unique biological and clinical features that differentiate from high-grade and other epithelial subtypes. Material and Methods. A comprehensive literature search was performed to identify interventional studies, systematic reviews, case reports, and meta-analyses published between 2010 and 2024, focusing on the diagnosis, management, and outcomes of low-grade serous ovarian carcinoma. Diagnosis. Ultrasound is the first-line imaging modality for evaluating ovarian and adnexal lesions. Computed tomography remains the preferred method for staging, treatment planning, and posttherapy monitoring, while magnetic resonance imaging is recommended for characterizing indeterminate adnexal masses or for evaluating extensive disease visualized on ultrasound or computed tomography. Clinical management. For patients with advanced-stage disease (FIGO stages II-IV), maximal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel remains the standard of care. Optimal cytoreduction is associated with significantly improved overall and progressionfree survival compared with suboptimal surgery. Given the intrinsic chemoresistance of low-grade serous ovarian carcinoma, primary cytoreductive surgery is generally favored over neoadjuvant chemotherapy. Emerging targeted therapies focusing on CDK4/6, MAPK, and PI3K/AKT/mTOR pathways, as well as hormonal treatments, are under investigation and have demonstrated encouraging preliminary results. Conclusion. The management of low-grade serous ovarian carcinoma increasingly necessitates an individualized, multidisciplinary approach. Future therapeutic strategies will likely integrate molecularly targeted and endocrine therapies with optimal cytoreductive surgery to improve outcomes for this chemoresistant and biologically distinct ovarian cancer subtype.